Notice of Intent to Publish a Funding Opportunity Announcement for Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)

0
2

Opportunity ID:333299
Opportunity Number:NOT-CA-21-060
Opportunity Title:Notice of Intent to Publish a Funding Opportunity Announcement for Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.395
93.396
Eligible Applicants:Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Additional Information on Eligibility:
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:May 04, 2021
Last Updated Date:Jun 25, 2021
Estimated Synopsis Post Date:Jun 01, 2021
Fiscal Year:2022
Award Ceiling:$1,000,000
Award Floor:
Estimated Total Program Funding:$8,182,000
Expected Number of Awards:5
Description:The National Cancer Institute (NCI) intends to publish a Funding Opportunity Announcement (FOA) as a Request for Applications (RFA) for Translational and Basic Science Research in Early Lesions (TBEL) Centers (U54). The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as “co-organizers” of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. Each TBEL Center shall have a unique thematic focus and be structured to test hypotheses that bridge basic and translational research in a synergistic and iterative fashion. Collectively, TBEL Centers will operate as a network that will inform future, rationally-design modes of intervention that are founded on strong biological mechanisms and be comprehensive, multi-dimensional, and appropriately tailored to the degree of malignant potential of an early lesion. This Notice is being provided to allow potential applicants sufficient time to develop a responsive, multicomponent TBEL application. The companion notice for the TBEL Coordinating and Data Management Center (CDMC; U24) is: NOT-CA-21-061. The FOA is expected to be published in Summer 2021 with an anticipated application due date in Fall 2021. Details of the planned pre-application webinar will be announced in the Guide after publication of the FOA. The FOA will utilize the U54 (Specialized Center–Cooperative Agreements) activity code.
Version:2





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here